
Pre-made Daratumumab benchmark antibody ( Whole mAb, anti-CD38 therapeutic antibody, Anti-ADPRC1/ADPRC 1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-133
Pre-Made Daratumumab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Daratumumab, sold under the brand name Darzalex, is an anti-cancer medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-133-1mg | 1mg | 3090 | ||
GMP-Bios-ab-133-10mg | 10mg | 21890 | ||
GMP-Bios-ab-133-100mg | 100mg | 148000 | ||
GMP-Bios-ab-133-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Daratumumab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody |
INN Name | Daratumumab |
Target | CD38 |
Format | Whole mAb |
Derivation | Human |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Approved |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2009 |
Year Recommended | 2010 |
Companies | Boston Medical Center;Bristol-Myers Squibb;Dana-Farber Cancer Institute;French Innovative Leukemia Organisation;Genentech;Genmab;Janssen Biotech;Janssen Research & Development;M. D. Anderson Cancer Center;Syros Pharmaceuticals |
Conditions Approved | Multiple myeloma |
Conditions Active | Amyloid light-chain amyloidosis;Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Myelodysplastic syndromes;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor T-cell lymphoblastic leukaemia-lymphoma;Prostate cancer;T-cell lymphoma;Waldenstrom's macroglobulinaemia;Solid tumours |
Conditions Discontinued | Non-small cell lung cancer |
Development Tech | Medarex HuMAb Mouse |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
